During this segment, David Quinn, MD, and Michael Kolodziej, MD, discuss the challenges clinicians face when developing a drug-sequencing plan for patients with castration-resistant prostate cancer.
Dr Quinn explains that because not all patients respond to the same types of therapy, there is a need for data that reveals the appropriateness of agents suggested in step therapy plans.
To address this challenge, he suggests that new clinical trials test comparative effectiveness, which he believes can help determine response rates for specific groups of patients.
Dr Kolodziej argues that receiving this data will take too long, and suggests receiving aid from professional services that can structure current data into an actionable format. He explains that this may help provide quick answers about step therapy and can improve the clinician’s decision-making process.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen